leer
leer
leer
DeutschEnglishImprint
navifuellAbout usleerTechnology PlatformleerProduct PipelineleerHow to PartnerleerInvestor RelationsleerNewsleerContactleer
linie
leer
leer
Strategy
Management
Supervisory Board
External Partners

 

bildmotiv1
Motivpunkte
leer
leer

Novaliq GmbH is a drug delivery company located in the Heidelberg Technology Park, Germany. They develop innovative pharmaceutical formulations based on semifluorinated alkanes (SFAs).

Their patented SFAs can be used in various routes of administration for the transport of drugs or oxygen for therapeutic purposes. Novaliq currently develops novel ophthalmic and dermatological products as well as solutions for organ preservation, based on the unique physicochemical properties of SFA.

Their first and preservative free eye drop product (OTC) is NovaTears® for the relief of discomfort under dry eye syndrome. The product is available in standard multi dose units.

Besides the development of its own products and licensing them to pharmaceutical distributors, Novaliq is offering its SFA technology as a delivery platform for external co-development cooperations.


>> Latest News



Press Release of May 5, 2016                                         

NOVALIQ ANNOUNCES LAST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF CYCLASOL® FOR THE TREATMENT OF MODERATE TO SEVERE DRY EYE DISEASE

 
leer

ARVO 2016 Poster

Omega 3 Fatty Acids Using F6H8-Carrier as Topical Therapy in Experimental Dry-Eye Disease



Watch the OIS Webcast Video:

Novaliq Goes After Dry Eye Disease


leer © 2016 Novaliq GmbH Germany. All rights reserved.